Monday's fresh ESMO zolucatetide readout details lift Parabilis
Monday's fresh ESMO zolucatetide readout details lift Parabilis 13% during regular trading
- Parabilis issued the release at 7:00 a.m. ET, before Monday’s opening bell
- It detailed updated Phase 1/2 zolucatetide data scheduled for ESMO on October 24
- The dataset covers dose escalation and optimization results through June 22, 2026
- Dose optimization will inform regimen selection for a planned registrational Phase 3 trial
- Monday’s release added cutoff, trial-arm, session and investor-webcast details to September guidance
- Shares opened approximately 1% higher, then gained roughly 12% during trading
- The 13.36% move modestly exceeded PBLS’s roughly 9.7% monthly average range
- No efficacy figures emerged; buying reflected anticipation of Saturday’s clinical-data readout
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.